Bristol-Myers close to selling $3B+ stake in diabetes JV to AZN


Bristol-Myers Squibb (BMY) is reportedly close to an agreement to sell its holdings in a diabetes joint venture to partner AstraZeneca (AZN) in a deal that could be worth over $3B.

A transaction would mark a sharp U-Turn in Bristol's strategy: last year the company increased its diabetes commitment by paying $5.3B to buy Amylin Pharmaceuticals, which was then incorporated into the JV with AZN. The latter paid Bristol $3.4B for a half share of Amylin's drugs.

However, sales from the partnership have been disappointing and Bristol is less persuaded about the market opportunity than AstraZeneca.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs